Whole-Genome Sequencing Will Change Pregnancy

World Pregnancy is about to change, the Nur Siddiqui predicts. “I think that people who choose to choose kids are through IVF and the fetal screening,” he said Cable health Summit conferences last week. “There is a lot of risk that you can open the table”

Siddiqui is the founder and CEO of Orchid, a Biotech company that offers Screening the whole genome Fetals for IVF. Analyzing the DNA of different embryos before selecting which one should be transplanted, orchid says parents can reduce the risk of suffering their children through genetic conditions. Siddiqui was talking to George Church, a pioneer of Genomics and a Professor-Boston summit of Harvard Medical School, searching for the entire genome sequencing promise and possibility.

An Approximately 4 percent of people worldwide have a disease that is caused by a single genetic mutation. Through the fetal screening, “these psychological diseases can only be completely avoided,” said Siddiqui. After all, about half of the world’s population suffer from chronic diseases at least some genetic basis. Analyze five embryos before a plan, Siddiqui said, “You can now mitigate this risk genetic material by this dual-digit number. You are talking up to 30 percent in the worst case and up to 80 percent in the best case.”

Orchid’s website, which Reference Statistical analysis on how much risk can be achieved through fetal screening explains that the correct decrease in relative risk will depend on various factors. These include, among others, how common the disease is, the number of fetuses has been analyzed, and the impact of the genetic forms displayed on the possibility of developing the disease.

An investor in the Church Orchid, and believes that the type of fetal screening it offers is among the most expensive treatment technologies built so far. Human genome project, the first attempt to map all human genes, cost $ 3 billion, but since then the cost of sequencing to the genome has been dramatically reduced. The entire genome sequencing of the orchid costs a thousand dollars per fetus. The Church believes that it can be “10 times the return for investment”. “A large part of our healthcare expenses, psychological problems and family problems can be solved by this method.”

Siddiqui used the technology to screen his own fetus. He shared the story of his mother, who had experienced the blindness of adults as a result of genetic changes in his genome. “Luckily, all the embryos are negative for him,” he said. “But the other thing that is quite common in most South Asian families is incredibly high risk for heart disease and diabetes so it is really the other thing we are giving priority.”

The blindness that Siddiqui describes is Manogenic, which means it was only because of a single genetic variety. Siddiqui said that in single gene diseases, “95 percent of the treatment has no treatment, very low to healing,” Siddiqui said. However, many other conditions such as schizophrenia, or bipolar disorder, or heart disease – polygamy powered by the growing influence of many genetic variants. For these, genetic risk scores can determine the risk of the potential development of a disease, and they can be calculated for both adults and fetuses. The embryo test of the orchid finds the type of both diseases.